Evoke Pharma receives CRL for Gimoti NDA; shares down 38% premarket SA News • Apr. About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat Gastrointestinal (GI) disorders and diseases. On March 4, the Solana Beach, Calif.-based company received a multi-disciplinary review (DR) letter from the FDA in association with its New Drug Application (NDA) for Gimotti. Shares of California-based Evoke Pharma have plunged more than 40 percent in premarket trading after the company announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the company’s gastroparesis treatment, Gimotti.. On March 4, the Solana Beach, Calif.-based company received a multi-disciplinary review (DR) letter from the FDA in association with its New Drug Application (NDA) for Gimotti. SOLANA BEACH - Evoke Pharma, Inc. , a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and … The FDA has accepted for review Evoke Pharma's (NASDAQ:EVOK) resubmitted marketing application for Gimoti (metoclopramide) nasal spray for the relief of symptoms in … About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Shares of California-based Evoke Pharma have plunged more than 40 percent in premarket trading after the company announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the company’s gastroparesis treatment, Gimotti.. Evoke Pharma’s Gimoti Runs Into Trouble Evoke Pharma ’s Gimoti has a target action date of April 1. 2, 2019 • 11 Comments Evoke Pharma up 19% premarket on response to FDA letter related to Gimoti NDA About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke Pharma Inc. Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The Company is … The Company is developing Gimoti, a nasal spray formulation of metoclopramide, for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. It failed a Phase III study three years ago, evis­cer­at­ing the stock. Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its … Evoke Pharma’s Gimoti Runs Into Trouble Evoke Pharma ’s Gimoti has a target action date of April 1. Evoke has done its ut­most to drag the drug to the fin­ish line, de­spite its che­quered past.